Search for: "Swiss v. Eli Lilly & Co."
Results 1 - 18
of 18
Sorted by Relevance
|
Sort by Date
5 Jul 2015, 4:18 am
Furthermore, the previous week the England and Wales Court of Appeal issued a decision in Actavis UK Ltd & Ors v Eli Lilly & Company [2015] EWCA Civ 555, which also involved Swiss-type claims.It is interesting to compare the two decisions, particularly because, in my view, the UK court managed to completely undermine the European prohibition on patents for methods of medical treatment and must surely, therefore, be wrong! [read post]
5 Oct 2022, 6:51 am
” In re Eli Lilly and Co., 37 F.4th 160 (4th Cir. 2022). [read post]
12 Jan 2023, 4:23 pm
Aug. 31, 2016) (issuing letter of request where witness was located in Italy and possessed evidence that was relevant and unlikely to be duplicative); Eli Lilly & Co. v. [read post]
27 Nov 2012, 8:43 am
And now, here is a legal first, straight from the pen (well, keyboard) of our Mr Justice Arnold in joined cases Actavis Group hf v Eli Lilly & Company (USA)/Medis ehf v Eli Lilly & Company (USA) [2012] EWHC 3316 (Pat) on whether the English Courts have jurisdiction over issues of infringement of foreign-designated patents. [read post]
5 Apr 2016, 6:32 am
It concerns Eli Lilly's patent with Swiss-type claims to the use of pemetrexed disodium and Vitamin B12 for the treatment of cancer. [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in India… [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in India… [read post]
10 Feb 2010, 4:47 pm
Patent for Induced Pluripotent Stem Cell Technology (Patent Docs) Products Actos (Pioglitazone) –US:Patent infringement complaint filed following a Paragraph IV certification: Takeda Pharmaceutical Co. et al. v. [read post]
29 Oct 2013, 10:39 am
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
28 Sep 2010, 3:14 pm
Eli Lilly & Co. [read post]
30 Apr 2019, 5:29 am
This focused on the three-step test of the Eli Lilly v Actavis UK Supreme Court decision and the subsequent UK cases applying that test. [read post]
18 Nov 2016, 12:44 am
The judge held that the “undue burden” concept in English law (particularly as outlined by Arnold J in Eli Lilly v Janssen in 2014) was not particularly helpful under Australian law. [read post]
9 Nov 2015, 7:39 am
The patent contained a Swiss form claim (claim 1), and an EPC 2000 claim (claim 3). [read post]
27 Jul 2011, 1:01 am
Willmar Schwabe GmbH & Co. [read post]
5 Jul 2008, 11:05 am
: (IP tango), China: Pfizer loses trade mark action against Jaingsu Lianhuan Pharmaceutical Co over 3D mark: (Rouse & Co International), India: More patents for new forms issued to generics: (Patent Circle), India: Gauri Kamath on drug ‘differential pricing’ in India: (Spicy IP), Mexico: Revised health supplies regulations promise changes for generics: (International Law Office), US: World drug pricing crisis: Congressmen criticise US Trade… [read post]
30 May 2008, 9:09 am
: (IP ThinkTank), (further discussion from IAM and e^(ip)) Illusory world of trade secret protection – Discussion of S Schreter’s article ‘Inside entrepreneurship: Patent protection isn’t only option’: (IPBiz) Global – Copyright Illegal art: (Patry Copyright Blog), Events 1-3 June: ACC Europe 2008 annual conference ‘Becoming a global legal manager: Developing the skills you will need to manage the… [read post]
9 May 2008, 10:30 pm
: (Afro-IP), (Managing Intellectual Property), Rwanda: Four years after AIDS drugs bill passed, first low cost meds may head to Rwanda: (GenericsWeb), US: Abbott’s first quarter lobbying tab hits $880,000: (Patent Docs), US: House Bill would expand federal drug pedigree requirements and preempt state requirements: (FDA Law Blog), US: Purchasing Canadian drugs and patent infringement: Litecubes decision: (Patently-O), US: Neuralstem seeks to reopen stayed patent case… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]
